Premium
COX‐2, TFF1, and Src define better prognosis in young patients with gastric cancer
Author(s) -
Schildberg Claus,
Abbas M.,
Merkel S.,
Agaimy A.,
Dimmler A.,
Schlabrakowski A.,
Croner R.,
Leupolt J.,
Hohenberger W.,
Allgayer H.
Publication year - 2013
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23416
Subject(s) - medicine , cancer , proto oncogene tyrosine protein kinase src , proportional hazards model , oncogene , carcinogenesis , immunohistochemistry , oncology , cohort , survival analysis , cancer survival , survival rate , pathogenesis , pathology , cell cycle , receptor
Background and Objectives Despite its dwindling occurrence, gastric cancer remains a leading cause of cancer related mortality worldwide. Molecular determinants of prognosis that impact survival are being sought out as a means to facilitate rational clinical decision‐making and enhance patient management. In this study, we evaluated three molecules implicated in gastric carcinogenesis and demonstrated that the differential expression of cyclooxygenase‐2 (COX‐2) and the viral oncogene homolog Src proteins could explain the differences in survival observed in patients older and younger than 50 years of age. Methods We evaluated 5‐year survival in a cohort of 423 gastric cancer patients using chronological age as a variable. Additionally, we assessed the protein expression of three molecules (COX‐2, TFF1, Src) implicated in the pathogenesis of gastric cancer using immunohistochemistry. Results We found that patients younger than 50 years of age had a better 5‐year survival rate in all tumor stages. We found that the expression of COX‐2 and Src correlated significantly with survival in this group without any significant impact attributable to TFF1. Conclusions Our study demonstrates that young gastric cancer patients have a better prognostic outlook that could in part be explained by the differential expression of COX‐2 and Src. J. Surg. Oncol. 2013; 108:409–413 . © 2013 Wiley Periodicals, Inc.